Loading...
Loading...
NBRV| Name | Value |
|---|---|
| Revenues | 8.8M |
| Cost of Revenue | 4.5M |
| Gross Profit | 4.3M |
| Operating Expense | 14.7M |
| Operating I/L | -10.4M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.0M |
| Pretax | -10.7M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -11.1M |
Nabriva Therapeutics plc is a biopharmaceutical company specializing in the development and commercialization of novel anti-infective agents. Their flagship products include SIVEXTRO, an antibacterial for acute bacterial skin and skin structure infections, and XENLETA, a pleuromutilin antibiotic for community-acquired bacterial pneumonia. The company also has a pipeline of products in development, including XENLETA for pediatric infections and other indications such as cystic fibrosis and prosthetic joint infections. Additionally, they are developing CONTEPO, an antibiotic for complicated urinary tract infections. Nabriva Therapeutics plc generates revenue through the sale of these innovative anti-infective treatments.
